EU and AstraZeneca Reach Agreement on Remaining COVID-19 Vaccine Doses

Strategic Insights -

The European Union and AstraZeneca have come to an agreement that will secure the delivery of the remaining COVID-19 vaccine doses to EU Member States under the terms of the Advance Purchase Agreement concluded on 27 August 2020. This agreement will also bring an end to the pending litigation before the Brussels Court. Commissioner for Health and Food Safety Stella Kyriakides stated that the settlement ensures the delivery of the remaining 200 million COVID-19 vaccine doses to the EU. Despite reaching a milestone of 70% full vaccination of the EU's adult population, there are significant differences in vaccination rates between Member States, and the continued availability of vaccines remains crucial.

Key Takeaways:

  • The EU and AstraZeneca have reached an agreement to secure the delivery of the remaining 200 million COVID-19 vaccine doses to Member States under the terms of the Advance Purchase Agreement concluded on 27 August 2020.
  • The agreement will also end the pending litigation before the Brussels Court.
  • AstraZeneca has committed to delivering an additional 135 million doses by the end of 2021 and the remaining 65 million doses by the end of March 2022.
  • The Commissioner for Health and Food Safety, Stella Kyriakides, stated that vaccine solidarity is the EU's trademark, and they aim to share at least 200 million doses of vaccines through COVAX with low and middle-income countries until the end of the year.
  • Member States will be provided with regular delivery schedules and capped rebates will apply in the event of any delayed doses.
  • The agreement brings the total number of doses delivered to 300 million, as agreed under the contract.

Statistics:

  • 200 million: The number of COVID-19 vaccine doses to be delivered by AstraZeneca to the EU.
  • 135 million: Additional doses to be delivered by AstraZeneca to the EU by the end of 2021.
  • 75 million: Number of doses to be delivered by AstraZeneca to the EU by the end of Q4 2021.
  • 60 million: Number of doses to be delivered by AstraZeneca to the EU by the end of Q3 2021.
  • 65 million: Remaining doses to be delivered by AstraZeneca to the EU by the end of March 2022.
  • 300 million: The total number of doses delivered to the EU under the contract.
  • 70%: The milestone of full vaccination of the EU's adult population.

Sources:

  • Al Bawaba (Albawaba.com)
  • SyndiGate Media Inc. (Syndigate.info)
  • European Commission (European strategy to accelerate the development, manufacturing and deployment of effective and safe vaccines against COVID-19)